‡a
Author's Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada
‡a
costperresponseforabataceptversusadalimumabinpatientswithseropositiveerosiveearlyrheumatoidarthritisintheusgermanyspainandcanada
‡A
Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada
‡9
1